To: Sergio H who wrote (3424 ) 10/22/2003 8:57:05 PM From: Arthur Radley Read Replies (1) | Respond to If you want a small biotech that IMO will have fantastic news within a matter of weeks (by mid-November) take a look at DSCO. They will be presenting Phase III data (actually they have for all practical purposes exposed it but due to the fact it will be reported in the Lancet publication this year, they have to hold back the minute details)soon and file an NDA shortly thereafter. What is unique about DSCO is they will have the first human surfactant that isn't made from minced up cows and pigs lungs. The natural human surfactant is what allows us to breathe in that it helps absorb oxygen and to maintain proper airflow through the respiratory system. The first application that DSCO will file approval for is for premature infants they don't have fully developed lungs at birth...thus the lack of normal surfactants and major cause of their deaths. This indication is small, however, the next trial results for ARDS adult is a huge $1B plus market and there is no current available treatment for this condition. Thus to clarify what ARDS is, think pneumonia, septic shock, smoke inhalation, near drowings, industrial accidents(chemical inhaled) and other traumas to the lung. And think down the road that this drug can be used as a drug delivery system via the lungs.
